Maxim Group Starts Coverage On Cancer Genetics (CGIX) with $6.0 Target; Techne (TECH)’s Sentiment Is 1.44

December 7, 2017 - By Ellis Scott

Among 6 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cancer Genetics has $8 highest and $6.0 lowest target. $6.50’s average target is 202.33% above currents $2.15 stock price. Cancer Genetics had 8 analyst reports since March 11, 2016 according to SRatingsIntel. The firm has “Neutral” rating by Janney Capital given on Friday, March 11. The stock has “Buy” rating by H.C. Wainwright on Thursday, September 21. Aegis Capital maintained Cancer Genetics, Inc. (NASDAQ:CGIX) rating on Tuesday, March 15. Aegis Capital has “Buy” rating and $8 target. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Wednesday, November 29 report. On Tuesday, August 15 the stock rating was maintained by H.C. Wainwright with “Buy”. Rodman & Renshaw initiated it with “Buy” rating and $6 target in Monday, September 26 report.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $4.82 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 66.01 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on February, 6. They expect $0.85 EPS, up 14.86% or $0.11 from last year’s $0.74 per share. TECH’s profit will be $31.84 million for 37.86 P/E if the $0.85 EPS becomes a reality. After $0.82 actual EPS reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 3.66% EPS growth.

Ratings analysis reveals 100% of Bio-Techne’s analysts are positive. Out of 2 Wall Street analysts rating Bio-Techne, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $115.0 while the high is $115.0. The stock’s average target of $115 is -10.66% below today’s ($128.72) share price. TECH was included in 2 notes of analysts from January 18, 2017. The rating was initiated by Citigroup on Thursday, February 9 with “Buy”. The stock has “Buy” rating by Deutsche Bank on Wednesday, January 18.

Sg Capital Management Llc holds 4.28% of its portfolio in Bio-Techne Corporation for 205,055 shares. Summit Creek Advisors Llc owns 129,202 shares or 3.13% of their US portfolio. Moreover, Brown Capital Management Llc has 3.09% invested in the company for 2.15 million shares. The New York-based Stone Run Capital Llc has invested 2.79% in the stock. Mairs & Power Inc, a Minnesota-based fund reported 1.45 million shares.

The stock increased 0.19% or $0.25 during the last trading session, reaching $128.72. About 146,825 shares traded. Bio-Techne Corporation (TECH) has risen 6.75% since December 7, 2016 and is uptrending. It has underperformed by 9.95% the S&P500.

It closed at $2.15 lastly. It is down 81.82% since December 7, 2016 and is uptrending. It has outperformed by 65.12% the S&P500.

Analysts await Cancer Genetics, Inc. (NASDAQ:CGIX) to report earnings on March, 22. They expect $-0.10 earnings per share, up 33.33% or $0.05 from last year’s $-0.15 per share. After $-0.16 actual earnings per share reported by Cancer Genetics, Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Investors sentiment decreased to 1.17 in 2017 Q2. Its down 1.54, from 2.71 in 2017Q1. It is negative, as 6 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 5 funds opened positions while 9 raised stakes. 2.76 million shares or 20.57% more from 2.29 million shares in 2017Q1 were reported. Vanguard Group has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Diker Mngmt Ltd invested in 0.11% or 65,315 shares. The New York-based Renaissance Limited Co has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Geode Capital Mgmt Ltd Company holds 0% or 87,279 shares. Wells Fargo And Com Mn reported 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Blackrock has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Northern Tru, a Illinois-based fund reported 32,122 shares. Morgan Stanley accumulated 18,828 shares. Perkins Cap Mngmt invested in 828,366 shares or 3.63% of the stock. Pnc Service Grp stated it has 6,000 shares or 0% of all its holdings. Barclays Public Limited Co owns 454 shares. Eam Investors Ltd reported 0.07% in Cancer Genetics, Inc. (NASDAQ:CGIX). Fincl Bank Of Montreal Can reported 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Royal Commercial Bank Of Canada invested 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Deutsche Bank Ag holds 300 shares.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $52.15 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: